BLRX BioLineRx Ltd.
Company Analysis
Latest News
BioLineRx reports second quarter revenue of $0.3M missing estimates amid GLIX1 clinical expansion
BioLineRx reported second quarter 2026 revenue of $0.3 million, falling short of analyst expectations of $0.5 million. The company reported a net loss...
BioLineRx Pairs Earnings Day With a Cash Lifeline — But at $3.75 Million, Is It Enough to Keep the Lights On?
Shares of BioLineRx surged 9.6% to $2.85 in early trading on August 31, as investors digested a twin catalyst: the company's second-quarter earnings release...
🟢 BioLineRx is trading 9.6% up in pre-market ahead of Q2 results
BioLineRx is trading 9.6% up at $2.85 after closing at $2.60 on August 28, 2026, ahead of scheduled second-quarter results. - Results are due before the...
BioLineRx Ltd Q2 2026 Earnings Preview: What Analysts Expect on August 31, 2026
For the Q2 2026 reporting period, BioLineRx is expected to post revenue of $0.50 million and a break-even EPS of $0.00, as the stock trades at $2.60 against a...
🔴 BioLineRx is trading 5% down today after announcing a $3.75 million financing
BioLineRx is trading 5.04% down now at $2.64 after announcing a $3.75 million registered direct offering and concurrent private placement on August 28,...
🔴 BioLineRx is trading 20.14% down in pre-market after no company-specific announcement was identified
BioLineRx is trading at $2.22, down -20.14%, after no company-specific announcement was identified for August 28, 2026. • The latest company release announced...
🟢 BioLineRx is trading 5.56% up today as broader markets strengthen
BioLineRx is trading 5.56% up now at $2.85 as broader markets strengthen. - Nasdaq is up 1.60% and S&P 500 is up 0.77%. - No clear company-specific...
🔴 BioLineRx is trading 5.69% down today — No clear company-specific catalyst identified
BioLineRx is trading 5.69% down at $2.65, with no clear company-specific catalyst identified for the August 26, 2026 decline. - BioLineRx announced on August...
🟢 BioLineRx is trading 7.84% up today as XBI gains 2.06%
BioLineRx is trading 7.84% up at $3.03, benefiting primarily from a stronger biotechnology sector. - XBI is up 2.06% during the regular session. - No new...
BioLineRx Ltd Q2 2026 Earnings Preview: What Analysts Expect on August 27, 2026
BioLineRx is projected to report Q2 2026 consensus revenue of $0.50 million and a break-even EPS of $0.00, with its current $2.85 share price trading well...
🟢 BioLineRx is trading 6.07% up today amid broader biotech strength
BioLineRx is trading 6.07% up at $3.02, extending its rebound amid recent biotech strength following positive clinical-trial news across the sector. - It has...
🟢 BioLineRx is trading 7.27% up today as biotech momentum strengthens
BioLineRx is trading 7.27% up at $3.10, with the move appearing primarily linked to strengthening biotechnology-sector momentum. - The volatile week included...
🟢 BioLineRx is trading 6.18% up today
BioLineRx is trading 6.18% up at $2.80, with no clearly dated company-specific announcement identified on August 18, 2026, to explain the advance. - The...
🟢 BioLineRx is trading 6.3% up today as September rate expectations support growth stocks
BioLineRx is trading 6.3% up now at $2.87 amid a broader risk-on session, as softer-than-expected July producer inflation and slightly higher jobless claims...
🟢 BioLineRx is trading 8.75% up today ahead of estimated August 13, 2026 Q2 earnings
BioLineRx is trading 8.75% up now at $3.00, as investors may also be positioning ahead of the estimated August 13, 2026 Q2 earnings release. - The stock...
BioLineRx Ltd Q2 2026 Earnings Preview: What Analysts Expect on August 13, 2026
BioLineRx is expected to report a Q2 2026 loss of $0.02 per share on revenue of $8.45 million, while the current stock price of $1.15 remains significantly...
🟢 BioLineRx is trading 16.91% up in pre-market — catalyst unconfirmed
BioLineRx is trading at $3.25, up 16.91%, with the catalyst unconfirmed. - The stock rose from its August 6 close of $2.79; searches found no clear...
🟢 BioLineRx is trading 7.9% up today as biotech sector rally continues
BioLineRx is trading at $2.95 (up 7.9%), extending its recent rebound amid a broader biotech sector rally and risk-on market sentiment. • The move follows a...
🟢 BioLineRx is trading 5.9% up today amid broad risk-on sentiment in the biotech sector
BioLineRx is trading at $2.81 (+5.85%) as shares move higher amid broad risk-on sentiment and a positive tone across the biotech sector. • The stock is...
🟢 BioLineRx is trading 5.3% up today in after-hours trading with no clear catalyst yet
BioLineRx is trading 5.3% higher at $2.79 in after-hours trading, recovering from a regular-session decline despite no new company-specific filings or news...